HC Wainwright Lowers Astria Therapeutics (NASDAQ:ATXS) Price Target to $16.00

Astria Therapeutics (NASDAQ:ATXS) had its target price reduced by analysts at HC Wainwright from $18.00 to $16.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective points to a potential upside of 77.78% from the company’s previous close.

A number of other brokerages also recently weighed in on ATXS. Wedbush reissued an “outperform” rating and set a $17.00 price target on shares of Astria Therapeutics in a research report on Tuesday, March 26th. Jefferies Financial Group boosted their price objective on Astria Therapeutics from $22.00 to $27.00 and gave the stock a “buy” rating in a report on Monday, March 25th.

Astria Therapeutics Trading Down 6.6 %

ATXS stock opened at $9.00 on Tuesday. The business’s 50-day moving average price is $13.31 and its two-hundred day moving average price is $9.27. The firm has a market cap of $494.13 million, a PE ratio of -3.85 and a beta of 0.69. Astria Therapeutics has a 1-year low of $4.26 and a 1-year high of $16.90.

Astria Therapeutics (NASDAQ:ATXS) last posted its earnings results on Monday, March 4th. The biotechnology company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.78) by ($0.08). On average, analysts forecast that Astria Therapeutics will post -1.55 earnings per share for the current year.

Insider Activity

In other Astria Therapeutics news, insider Christopher Morabito sold 9,200 shares of Astria Therapeutics stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $11.15, for a total transaction of $102,580.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Astria Therapeutics news, insider Christopher Morabito sold 9,200 shares of Astria Therapeutics stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $11.15, for a total transaction of $102,580.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Perceptive Advisors Llc purchased 2,481,350 shares of the business’s stock in a transaction on Thursday, February 1st. The shares were bought at an average price of $12.09 per share, with a total value of $29,999,521.50. Following the purchase, the director now directly owns 4,873,721 shares in the company, valued at approximately $58,923,286.89. The disclosure for this purchase can be found here. 3.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Astria Therapeutics

Hedge funds have recently modified their holdings of the stock. AJOVista LLC bought a new stake in shares of Astria Therapeutics in the 4th quarter worth approximately $51,000. Jump Financial LLC purchased a new position in shares of Astria Therapeutics during the 3rd quarter valued at $111,000. Panagora Asset Management Inc. purchased a new position in shares of Astria Therapeutics during the 4th quarter valued at $119,000. Trexquant Investment LP purchased a new position in shares of Astria Therapeutics during the 4th quarter valued at $409,000. Finally, ADAR1 Capital Management LLC purchased a new position in shares of Astria Therapeutics during the 4th quarter valued at $1,469,000. Institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.